Epitan receives marketing approval for Zindaclin

By Ruth Beran
Tuesday, 08 November, 2005

Epitan (ASX:EPT, ADR:EPTNY, XETRA:UR9) has received approval from the Therapeutic Goods Administration (TGA) for the registration of anti-acne treatment Zindaclin.

Zindaclin is a once-a-day clindamycin-based gel which Epitan's wholly-owned subsidiary Epipharm in-licensed from UK-based Pro-Strakan Pharmaceuticals (formerly Strakan) in July 2004. The product was submitted for registration from the TGA soon after.

AusBiotech partners with Tenmile

Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...

Australian CDC issues update in wake of Ebola outbreak

After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...

Australia announces $7.2m diphtheria outbreak response package

To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...

Content from other channels on our network

Sydney next to welcome electric hydrofoiling vessels

Newcastle Airport receives 5 Star Green Star Buildings certification

COP31 electrification target announced

Councils named as best 'impossible-to-recycle' recyclers

New Qld expo focuses on waste and recycling

SEKO IoT solutions revolutionise on-premise laundry dosing

Six key pillars of frailty prevention and management

Protecting the people who protect us: PPE continuity during demand surge

WA steps in to ensure 'continuity' of operations at Mount Private Hospital

What healthcare boards need from risk leaders

Driving food safety through digital traceability and transparency

New analytical method for testing gluten-free beer assessed

Mars expands local pet food production with new $112.6m facility now open

From Factory Floor to Finished Product: CeMAT Australia 2026 Puts Food and Beverage Supply Chains in Focus

Leadership changes at Roma Foods, CEO to step down